$Novo-Nordisk A/S(NVO)$ COPENHAGEN, Jan 5 (Reuters) - Denmark's Novo Nordisk NOVOb.CO will offer its 1.5 and 4 milligram Wegovy weightloss pills at $149 per month to self-paying patients in the United States from January 5, it said on Monday. It will offer the highest doses of the drug pill, of 9 and 25 milligram, at $299 per month, it said on its website.
$CoreWeave, Inc.(CRWV)$ Mizuho Securities analyst Gregg Moskowitz upgrades $CoreWeave (CRWV.US)$ to a buy rating, and adjusts the target price from $92 to $135.